Adjuvant Chemotherapy Combined With Trastuzumab in the Randomized Phase III Trial N9831 Actively Immunizes Patients Against Tumor Antigens [SUBSTUDY OF 700003274]
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 19 Jul 2016 Planned primary completion date changed from 1 Feb 2013 to 1 Jan 2100.
- 19 Jul 2016 Status changed from completed to active, no longer recruiting.
- 04 Jun 2013 Status changed from active, no longer recruiting to completed, according to presentation of results.